MX2022004394A - Moduladores de receptor alfa relacionado con estrogenos (erra). - Google Patents
Moduladores de receptor alfa relacionado con estrogenos (erra).Info
- Publication number
- MX2022004394A MX2022004394A MX2022004394A MX2022004394A MX2022004394A MX 2022004394 A MX2022004394 A MX 2022004394A MX 2022004394 A MX2022004394 A MX 2022004394A MX 2022004394 A MX2022004394 A MX 2022004394A MX 2022004394 A MX2022004394 A MX 2022004394A
- Authority
- MX
- Mexico
- Prior art keywords
- erra
- estrogen
- receptor modulators
- alpha receptor
- related alpha
- Prior art date
Links
- 102100036832 Steroid hormone receptor ERR1 Human genes 0.000 abstract 3
- 108091008559 estrogen-related receptor alpha Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
La presente invención está dirigida a compuestos de acuerdo con la Fórmula I y las sales farmacéuticamente aceptables de los mismos. Los compuestos se pueden usar como moduladores del receptor alfa relacionado con estrógenos (ERRa) y tienen utilidad en el tratamiento de enfermedades o afecciones mediadas por ERRa. (I).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19204189 | 2019-10-18 | ||
| PCT/EP2020/079166 WO2021074365A1 (en) | 2019-10-18 | 2020-10-16 | ESTROGEN-RELATED RECEPTOR ALPHA (ERRα) MODULATORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022004394A true MX2022004394A (es) | 2022-05-18 |
Family
ID=68296174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022004394A MX2022004394A (es) | 2019-10-18 | 2020-10-16 | Moduladores de receptor alfa relacionado con estrogenos (erra). |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20240150342A1 (es) |
| EP (1) | EP4045503B1 (es) |
| JP (1) | JP7629912B2 (es) |
| KR (1) | KR20220084355A (es) |
| CN (1) | CN114630827B (es) |
| AU (1) | AU2020365434A1 (es) |
| BR (1) | BR112022006906A2 (es) |
| CA (1) | CA3151045A1 (es) |
| CO (1) | CO2022003829A2 (es) |
| ES (1) | ES2970386T3 (es) |
| HR (1) | HRP20240237T1 (es) |
| HU (1) | HUE066262T2 (es) |
| IL (1) | IL291523B2 (es) |
| MA (1) | MA57379B1 (es) |
| MX (1) | MX2022004394A (es) |
| PH (1) | PH12022550627A1 (es) |
| PL (1) | PL4045503T3 (es) |
| RS (1) | RS64986B1 (es) |
| WO (1) | WO2021074365A1 (es) |
| ZA (1) | ZA202203025B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117836296A (zh) * | 2021-08-03 | 2024-04-05 | 百济神州有限公司 | 吡唑并吡啶酮化合物 |
| WO2023165525A1 (en) * | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
| JP2025508971A (ja) | 2022-03-01 | 2025-04-10 | インシリコ メディスン アイピー リミティド | ジアシルグリセロールキナーゼ（ＤＧＫ）α阻害剤及びその使用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200902508A (en) * | 2007-03-07 | 2009-01-16 | Janssen Pharmaceutica Nv | Substituted phenoxy thiazolidinediones as estrogen related receptor-α modulators |
| EP2789615B1 (en) * | 2009-08-11 | 2017-05-03 | Bristol-Myers Squibb Company | Azaindazoles as Btk kinase modulators and use thereof |
| CN105246890A (zh) * | 2013-03-14 | 2016-01-13 | 艾伯维公司 | 吡咯并[2,3-b]吡啶cdk9激酶抑制剂 |
-
2020
- 2020-10-16 WO PCT/EP2020/079166 patent/WO2021074365A1/en not_active Ceased
- 2020-10-16 JP JP2022522032A patent/JP7629912B2/ja active Active
- 2020-10-16 HR HRP20240237TT patent/HRP20240237T1/hr unknown
- 2020-10-16 BR BR112022006906A patent/BR112022006906A2/pt unknown
- 2020-10-16 MA MA57379A patent/MA57379B1/fr unknown
- 2020-10-16 MX MX2022004394A patent/MX2022004394A/es unknown
- 2020-10-16 HU HUE20792415A patent/HUE066262T2/hu unknown
- 2020-10-16 IL IL291523A patent/IL291523B2/en unknown
- 2020-10-16 ES ES20792415T patent/ES2970386T3/es active Active
- 2020-10-16 EP EP20792415.0A patent/EP4045503B1/en active Active
- 2020-10-16 PH PH1/2022/550627A patent/PH12022550627A1/en unknown
- 2020-10-16 AU AU2020365434A patent/AU2020365434A1/en active Pending
- 2020-10-16 RS RS20231236A patent/RS64986B1/sr unknown
- 2020-10-16 US US17/754,902 patent/US20240150342A1/en not_active Abandoned
- 2020-10-16 CN CN202080072119.3A patent/CN114630827B/zh active Active
- 2020-10-16 KR KR1020227016464A patent/KR20220084355A/ko not_active Ceased
- 2020-10-16 PL PL20792415.0T patent/PL4045503T3/pl unknown
- 2020-10-16 CA CA3151045A patent/CA3151045A1/en active Pending
-
2022
- 2022-03-14 ZA ZA2022/03025A patent/ZA202203025B/en unknown
- 2022-03-29 CO CONC2022/0003829A patent/CO2022003829A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL291523B1 (en) | 2023-08-01 |
| JP7629912B2 (ja) | 2025-02-14 |
| IL291523A (en) | 2022-05-01 |
| PH12022550627A1 (en) | 2023-03-13 |
| MA57379B1 (fr) | 2024-02-29 |
| PL4045503T3 (pl) | 2024-05-06 |
| IL291523B2 (en) | 2023-12-01 |
| HRP20240237T1 (hr) | 2024-05-10 |
| RS64986B1 (sr) | 2024-01-31 |
| EP4045503B1 (en) | 2023-12-06 |
| CO2022003829A2 (es) | 2022-07-08 |
| ZA202203025B (en) | 2023-12-20 |
| JP2023501081A (ja) | 2023-01-18 |
| EP4045503C0 (en) | 2023-12-06 |
| CA3151045A1 (en) | 2021-04-22 |
| EP4045503A1 (en) | 2022-08-24 |
| WO2021074365A1 (en) | 2021-04-22 |
| AU2020365434A1 (en) | 2022-05-26 |
| US20240150342A1 (en) | 2024-05-09 |
| KR20220084355A (ko) | 2022-06-21 |
| BR112022006906A2 (pt) | 2022-07-05 |
| CN114630827B (zh) | 2024-09-03 |
| ES2970386T3 (es) | 2024-05-28 |
| HUE066262T2 (hu) | 2024-07-28 |
| CN114630827A (zh) | 2022-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022003829A2 (es) | Moduladores de receptor alfa relacionado con estrógenos (errα) | |
| CO2021017619A2 (es) | Moduladores del receptor alfa relacionado con estrógeno (errα) | |
| CL2022003510A1 (es) | Inhibidores de cisteína proteasas y sus métodos de uso | |
| CO2021008998A2 (es) | Amidas de pirrolidina iii sustituidas | |
| SV2019005823A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| ECSP11011512A (es) | Enantiómeros de compuestos de espirooxindol y sus usos como agentes terapéuticos | |
| UY37848A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
| CL2022001710A1 (es) | Derivados bicíclicos sustituidos de piperidina útiles como activadores de células t | |
| DOP2011000371A (es) | Derivados de l-(pireridin-4-il)-pirazol como moduladores de gpr 119 | |
| MX374728B (es) | MODULADORES DE ROR GAMMA (RORy). | |
| CO6781497A2 (es) | Tratamiento para la lipodistrofia | |
| MX388641B (es) | Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. | |
| MX2020008107A (es) | Moduladores del receptor nmda espiro-lactama y usos de los mismos. | |
| MX2022011333A (es) | Compuestos moduladores de gpr52. | |
| CO2021012579A2 (es) | Compuestos útiles en la terapia del vih | |
| ECSP21003718A (es) | Derivados de triazolquinoxalina adicionalmente sustituidos | |
| MX377329B (es) | Moduladores de ror gamma (ror?). | |
| CL2021000329A1 (es) | Compuestos útiles en terapia del vih | |
| MX378111B (es) | Moduladores de ror gamma (ror?). | |
| CL2020003248A1 (es) | Derivados de tetrahidrotienopiridina n-sustituidos y sus usos | |
| ECSP20082988A (es) | Agonistas de tlr7 | |
| MX386293B (es) | Compuestos de aminoindano y su uso en el tratamiento del dolor. | |
| DOP2016000311A (es) | Nuevos compuestos | |
| DOP2019000119A (es) | Moduladores de ROR gamma (RORy) | |
| CO2021004612A2 (es) | Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamento |